BSC 1601
Alternative Names: BSC-1601Latest Information Update: 06 Jul 2023
At a glance
- Originator BiSiChem
- Class Antifibrotics; Hepatoprotectants; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Fibrosis; Non-alcoholic steatohepatitis
Most Recent Events
- 27 Jun 2023 BSC 1601 is available for licensing as of 27 Jun 2023. https://bisichem.com/default/#about (BiSiChem website, June 2023)
- 27 Jun 2023 Early research in Fibrosis in South Korea (unspecified route) before June 2023 (BiSiChem pipeline, June 2023)
- 27 Jun 2023 Early research in Non-alcoholic steatohepatitis in South Korea (unspecified route) before June 2023 (BiSiChem pipeline, June 2023)